PMC:7172841 / 849-1068
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T9 | 19-25 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T10 | 36-39 | Body_part | denotes | HLA | http://purl.org/sig/ont/fma/fma84795 |
T11 | 207-218 | Body_part | denotes | lymphocytes | http://purl.org/sig/ont/fma/fma62863 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T13 | 0-8 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T14 | 0-4 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T10 | 19-25 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
T11 | 124-129 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T5 | 40-42 | Chemical | denotes | DR | http://purl.obolibrary.org/obo/CHEBI_73445 |
T6 | 94-96 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
T8 | 124-129 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T9 | 0-219 | Sentence | denotes | SARS-CoV-2 patient plasma inhibited HLA-DR expression, and this was partially restored by the IL-6 blocker Tocilizumab; off-label Tocilizumab treatment of patients was accompanied by increase in circulating lymphocytes. |
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T29 | 0-10 | SP_7 | denotes | SARS-CoV-2 |
T30 | 19-25 | UBERON:0001969 | denotes | plasma |
T31 | 36-39 | PR:000029150 | denotes | HLA |
T32 | 43-53 | GO:0010467 | denotes | expression |
T33 | 94-98 | PR:000001393 | denotes | IL-6 |
T34 | 107-118 | DG_35 | denotes | Tocilizumab |
T35 | 130-141 | DG_35 | denotes | Tocilizumab |
T36 | 195-206 | CL:0000080 | denotes | circulating |
T37 | 207-218 | CL:0000542 | denotes | lymphocytes |
T85947 | 0-10 | SP_7 | denotes | SARS-CoV-2 |
T29939 | 19-25 | UBERON:0001969 | denotes | plasma |
T8998 | 36-39 | PR:000029150 | denotes | HLA |
T62491 | 43-53 | GO:0010467 | denotes | expression |
T78149 | 94-98 | PR:000001393 | denotes | IL-6 |
T18501 | 107-118 | DG_35 | denotes | Tocilizumab |
T10312 | 130-141 | DG_35 | denotes | Tocilizumab |
T74668 | 195-206 | CL:0000080 | denotes | circulating |
T90672 | 207-218 | CL:0000542 | denotes | lymphocytes |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
42 | 94-98 | Gene | denotes | IL-6 | Gene:3569 |
46 | 0-10 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
47 | 11-18 | Species | denotes | patient | Tax:9606 |
48 | 155-163 | Species | denotes | patients | Tax:9606 |
51 | 107-118 | Chemical | denotes | Tocilizumab | MESH:C502936 |
52 | 130-141 | Chemical | denotes | Tocilizumab | MESH:C502936 |